VOOPOO
7.1.2022 13:02:14 CET | Business Wire | Press release
At the start of the new year 2022, VOOPOO , always in pursuit of unique industrial designs, has made another big move. On January 5, it launched Vinci Pod Royal Edition with a new relief design. Its shining and lightweight overall shape emphasizes a retro feel while also showing a strong aristocratic atmosphere.
Original relief craftsmanship for Pod
A large number of relief artworks have been unearthed from the ancient Sumerian Ruins, one of the birthplaces of human civilization. In contemporary times, there are also plenty of art products using relief craftsmanship. According to Vivian, Head of VOOPOO Product Development Team, “It is precisely the ancient relief artworks and the fashionable and retro contemporary elements that inspired us to develop the Vinci Pod Royal Edition series. Our original purpose is to explore the artistic and cultural value of the Pod product itself, so that users can also show their artistic taste in the process of using the product.”
However, it is no easy to engrave relief patterns on delicate Pod products. Any slight fault in the process will result in failure to achieve art-grade quality. The six products of the VOOPOO Vinci Pod Royal Edition series are all designed by experienced artists and are also integrated with design elements from retro jazz and cool graffiti styles. Product development took 8 months, and 12 manufacture processes and 68 techniques were involved, with 80% of the work completed by hand. The products were a result of the collaboration of more than 20 people including industrial designers, structural designers, and R&D members.
In addition to the unique relief itself, the tactile experience brought by the relief is even more impressive. Since the relief pattern of each product is different, customers can choose according to their own visual and tactile preferences. When the Pod of "tactile beauty" is held in your hand, you can experience an artistic masterpiece with its concave-convex surface, allowing you to enjoy a noble experience at your fingertip.
Focused on the user's product experience
In addition to the appearance, the product’s material and user experience also fit the users’ habits. The VOOPOO product development team has chosen the 6061 aviation-grade aluminum alloy, which boasts excellent strength, plasticity, fracture toughness, fatigue resistance, stress corrosion cracking resistance and exfoliation corrosion resistance, and has been widely used in aerospace, high-speed rail and automotive industries. It is worth noting that after 268 precise airflow experiments, the transmitter and airway design of VINCI Pod Royal Edition has been well optimized, bringing unparalleled comfort to the mouth-sucking experience.
VINCI Pod Royal Edition comes with the visual VINCI POD cartridge, which allows users to see the remaining e-liquid in real time, so that they can refill in time and refrain from anxiety. At the same time, VINCI Pod Royal Edition is equipped with 0.8Ω and 1.2Ω atomizers for users to enjoy different levels of taste and nicotine experience according to their preferences. VINCI Pod Royal Edition has also perfectly integrated the breathing light, so that it lights up when the user is inhaling, and goes off when stopping, providing users the strong dynamic sense.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
Voopoo website: https://www.voopoo.com/
IG: https://www.instagram.com/voopoo_global/
https://www.instagram.com/voopootechofficial/
Facebook: https://www.facebook.com/Voopootech/
Tiktok: https://www.tiktok.com/@voopoo_indonesia?lang=en
Please view the original press release at businesswire.com: https://www.businesswire.com/news/home/20220105006068/zh-CN/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom